- Home
- CKPT vs KGEI Comparison
CKPT vs KGEI Comparison
Compare CKPT & KGEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- KGEI
- Stock Information
- Founded
- CKPT 2014
- KGEI 2008
- Country
- CKPT United States
- KGEI United States
- Employees
- CKPT N/A
- KGEI 8
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- KGEI
- Sector
- CKPT Health Care
- KGEI
- Exchange
- CKPT Nasdaq
- KGEI Nasdaq
- Market Cap
- CKPT 151.9M
- KGEI 250.1M
- IPO Year
- CKPT 2017
- KGEI N/A
- Fundamental
- Price
- CKPT $3.00
- KGEI $7.02
- Analyst Decision
- CKPT Strong Buy
- KGEI
- Analyst Count
- CKPT 2
- KGEI 0
- Target Price
- CKPT $13.50
- KGEI N/A
- AVG Volume (30 Days)
- CKPT 998.1K
- KGEI 55.8K
- Earning Date
- CKPT 11-12-2024
- KGEI 11-12-2024
- Dividend Yield
- CKPT N/A
- KGEI N/A
- EPS Growth
- CKPT N/A
- KGEI 2.07
- EPS
- CKPT N/A
- KGEI 0.48
- Revenue
- CKPT $47,000.00
- KGEI $54,654,000.00
- Revenue This Year
- CKPT N/A
- KGEI $15.83
- Revenue Next Year
- CKPT $172,016.02
- KGEI $23.96
- P/E Ratio
- CKPT N/A
- KGEI $14.62
- Revenue Growth
- CKPT N/A
- KGEI 16.56
- 52 Week Low
- CKPT $1.38
- KGEI $2.84
- 52 Week High
- CKPT $4.50
- KGEI $7.09
- Technical
- Relative Strength Index (RSI)
- CKPT 38.29
- KGEI 76.63
- Support Level
- CKPT $3.07
- KGEI $6.00
- Resistance Level
- CKPT $3.42
- KGEI $6.28
- Average True Range (ATR)
- CKPT 0.21
- KGEI 0.42
- MACD
- CKPT -0.03
- KGEI 0.06
- Stochastic Oscillator
- CKPT 4.94
- KGEI 94.17
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About KGEI Kolibri Global Energy Inc. Common stock
Kolibri Global Energy Inc is a North American energy company focused on finding and exploiting energy projects in oil, gas, and clean and sustainable energy. It is focused on the acquisition, exploration, and production of oil and gas reserves. The company owns and operates shale oil and gas properties in the United States. Its segments include the United States, Canada and Others. The company derives a majority of its revenue from the United States.